|Source||Humanized (from mouse)|
|Other names||AMG 785, romosozumab-aqqg|
|Chemical and physical data|
|Molar mass||145.9 kg/mol g·mol−1|
|(what is this?)|
Romosozumab, sold under the brand name Evenity, is a medication used to treat osteoporosis. It has been found to decrease the risk of fractures of the spine. Common side effect include headache, joint pain, and pain at the site of injection. It may increase the risk of heart attacks, strokes, and deaths from cardiovascular disease.
It is a humanized monoclonal antibody that targets sclerostin. Research shows the drug increases bone formation and decreases bone resorption in postmenopausal women with low bone density. Romosozumab was approved for medical use in the United States in 2019.
In 2016, results from 12 months of a clinical study were reported. Patients given romosozumab had a lower risk of vertebral fracture than patients given a placebo.
Romosozumab was approved for medical use in the United States in 2019. It was originally discovered by Chiroscience, which was acquired by Celltech (now[when?] owned by UCB). Celltech entered in a partnership with Amgen in 2002 for the product's development.
- "FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture". www.fda.gov (Press release). 9 April 2019. Retrieved 12 April 2019.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Romosozumab" (PDF). American Medical Association. Archived from the original (PDF) on 29 September 2012.
- Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. (October 2016). "Romosozumab Treatment in Postmenopausal Women with Osteoporosis". The New England Journal of Medicine. 375 (16): 1532–1543. doi:10.1056/NEJMoa1607948. PMID 27641143.
- Quested T (7 June 2015). "Cream of life science entrepreneurs' first venture was selling doughnuts". Business Week. Cambridge, England: Q Communications. Retrieved 24 December 2018.
- Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, et al. (December 2003). "Osteocyte control of bone formation via sclerostin, a novel BMP antagonist". The EMBO Journal. 22 (23): 6267–76. doi:10.1093/emboj/cdg599. PMC 291840. PMID 14633986.
- "Celltech group Interim Report 2002" (PDF). Celltech Group plc.
- "Romosozumab". Drug Information Portal. U.S. National Library of Medicine.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.|